GlassScriptPhysician profile
Barry J Cukor
NPI 1316115595
$6,803.29
in general payments reported to CMS, 2019-2025
37 companies · $946 in 2025
The $946 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $1,006 · 2021: $1,307 · 2022: $1,043 · 2023: $795 · 2024: $1,002 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,513.26 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $611.96 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $516.98 | 2019-2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $473.14 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $276.13 | 2019-2023 | |
| Genzyme Corporation | $267.09 | 2024-2025 | |
| Pfizer INC. | $255.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $217.71 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $209.93 | 2019-2024 | Injectafer |
| Intercept Pharmaceuticals, INC. | $167.85 | 2020-2025 | Ocaliva |
| Qol Medical, LLC | $149.64 | 2019-2023 | Sucraid |
| Amgen INC. | $135.02 | 2020-2023 | Amjevita, Avsola |
| Redhill Biopharma INC. | $110.08 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $108.78 | 2020-2021 | |
| Celgene Corporation | $108.49 | 2022-2024 | Zeposia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $75.46 | 2021-2024 | Givlaari |
| Endo Pharmaceuticals INC. | $61.12 | 2020-2021 | |
| Braintree Laboratories, INC. | $42.45 | 2020-2023 | Sutab |
| Organon LLC | $42.35 | 2021-2023 | Renflexis |
| Ferring Pharmaceuticals INC. | $40.86 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $37.29 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $36.93 | 2025 | Voquezna |
| Lilly USA, LLC | $34.03 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $31.74 | 2024 | Bylvay, Iqirvo |
| Aimmune Therapeutics, INC. | $31.28 | 2023 | |
| Shionogi INC | $29.36 | 2019 | |
| Novo Nordisk INC | $28.48 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $27.58 | 2025 | Rezdiffra |
| Olympus America INC. | $21.94 | 2025 | Single Use Aspiration Needle Na-U200h |
| Romark Laboratories, Lc | $21.25 | 2019 | |
| Fresenius Kabi USA, LLC | $21.23 | 2023 | Idacio |
| Regeneron Healthcare Solutions, INC. | $18.88 | 2023 | Dupixent |
| Shire North American Group INC | $18.55 | 2019 | |
| Vivus LLC | $17.11 | 2020 | |
| Orphalan INC | $16.29 | 2025 | Cuvrior |
| Pharmacosmos Therapeutics INC. | $15.30 | 2020 | |
| Angiodynamics, INC. | $12.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Cukor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.